Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
These results support the use of pretreatment measurement of AMH in predicting ovarian function loss in premenopausal women with HER2-positive eBC receiving chemotherapy and anti-HER2 therapy. Measurement of AMH at the end of treatment had reduced accuracy than pretreatment but in combination added slightly to the value of pretreatment sampling.
Authors
- David Cameron (ORCID: https://orcid.org/0000-0002-2717-7979)
- Dennis J. Slamon (ORCID: https://orcid.org/0000-0002-6330-498X)
- Richard A. Anderson (ORCID: https://orcid.org/0000-0002-7495-518X)
- Ian E. Krop (ORCID: https://orcid.org/0000-0002-6380-5944)
- G. Bobba
- Ruediger P. Laubender (ORCID: https://orcid.org/0000-0003-0832-1493)
- Chiara Lambertini (ORCID: https://orcid.org/0000-0003-4497-3296)
- Sanne de Haas (ORCID: https://orcid.org/0000-0001-7040-8763)
- Charles E. Geyer (ORCID: https://orcid.org/0000-0002-2379-5702)
- Sandra M. Swain (ORCID: https://orcid.org/0000-0002-1320-3830)
- Eleonora Restuccia (ORCID: https://orcid.org/0000-0001-5751-094X)
- Eric P. Winer (ORCID: https://orcid.org/0000-0002-8819-1723)
- Deirdre Allegranza (ORCID: https://orcid.org/0009-0001-5838-2887)
- Matteo Lambertini (ORCID: https://orcid.org/0000-0003-1797-5296)
- Inês Vaz-Luís (ORCID: https://orcid.org/0000-0002-7194-2260)
- Nadia Harbeck
Institutions
- Roche (Switzerland) (CH)
- NHS Lothian (GB)
- Inserm (FR)
- University of California, Los Angeles (US)
- Georgetown University (US)
- Université Paris-Saclay (FR)
- Georgetown University Medical Center (US)
- Western General Hospital (GB)
- Institut Gustave Roussy (FR)
- Edinburgh Cancer Research (GB)
- Rotary International (US)
- Yale Cancer Center (US)
- Délégation Ile-de-France Villejuif (FR)
- Pathways Behavioral Services (US)
- Roche Pharma AG (Germany) (DE)
- MRC Centre for Regenerative Medicine (GB)
- MRC Centre for Reproductive Health (GB)
- Laboratoire d'études sur les monothéismes (FR)
- Breast Center (CH)
- UPMC Hillman Cancer Center (US)
- Ospedale Policlinico San Martino (IT)
- CS Diagnostics (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Genoa (IT)
- MedStar Health (US)
- University of Edinburgh (GB)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-07-25
- DOI
- https://doi.org/10.1093/jnci/djaf198
- Citations
- 4
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.79
Funders
- F. Hoffmann-La Roche
- Associazione Italiana per la Ricerca sul Cancro
- Genentech